BR112021020499A2 - Monitoramento de terapia de gene - Google Patents

Monitoramento de terapia de gene

Info

Publication number
BR112021020499A2
BR112021020499A2 BR112021020499A BR112021020499A BR112021020499A2 BR 112021020499 A2 BR112021020499 A2 BR 112021020499A2 BR 112021020499 A BR112021020499 A BR 112021020499A BR 112021020499 A BR112021020499 A BR 112021020499A BR 112021020499 A2 BR112021020499 A2 BR 112021020499A2
Authority
BR
Brazil
Prior art keywords
gene therapy
technologies
things
monitoring
therapy monitoring
Prior art date
Application number
BR112021020499A
Other languages
English (en)
Inventor
Nelson Chau B
Jing Liao
Susana Gordo
Original Assignee
Logicbio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Logicbio Therapeutics Inc filed Critical Logicbio Therapeutics Inc
Publication of BR112021020499A2 publication Critical patent/BR112021020499A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

monitoramento de terapia de gene. a presente invenção refere-se, dentre outras coisas, a tecnologias para melhorar a terapia de gene. dentre outras coisas, a presente divulgação fornece tecnologias que permitem monitorar e/ou avaliar uma ou mais características de um tratamento de terapia de gene, tal como, por exemplo, extensão, nível e/ou persistência de expressão de carga útil. em algumas modalidades, fornecidas tecnologias particularmente úteis com integração de terapia de gene.a presente invenção refere-se, dentre outras coisas, a tecnologias para melhorar a terapia de gene. dentre outras coisas, a presente divulgação fornece tecnologias que permitem monitorar e/ou avaliar uma ou mais características de um tratamento de terapia de gene, tal como, por exemplo, extensão, nível e/ou persistência de expressão de carga útil. em algumas modalidades, fornecidas tecnologias particularmente úteis com integração de terapia de gene.
BR112021020499A 2019-04-15 2020-04-14 Monitoramento de terapia de gene BR112021020499A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962833875P 2019-04-15 2019-04-15
PCT/US2020/028102 WO2020214582A1 (en) 2019-04-15 2020-04-14 Monitoring gene therapy

Publications (1)

Publication Number Publication Date
BR112021020499A2 true BR112021020499A2 (pt) 2021-12-07

Family

ID=72837570

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020499A BR112021020499A2 (pt) 2019-04-15 2020-04-14 Monitoramento de terapia de gene

Country Status (13)

Country Link
US (1) US20220308070A1 (pt)
EP (1) EP3955972A4 (pt)
JP (1) JP2022529433A (pt)
KR (1) KR20220021906A (pt)
CN (1) CN114072181A (pt)
AU (1) AU2020258371A1 (pt)
BR (1) BR112021020499A2 (pt)
CA (1) CA3135666A1 (pt)
IL (1) IL287186A (pt)
MA (1) MA55727A (pt)
MX (1) MX2021012541A (pt)
SG (1) SG11202110584TA (pt)
WO (1) WO2020214582A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230098A1 (en) 2022-05-23 2023-11-30 Logicbio Therapeutics, Inc. Gene therapy compositions and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632800B1 (en) * 1999-08-17 2003-10-14 Mayo Foundation For Medical Education And Research System for monitoring the expression of transgenes
EP1636360A4 (en) * 2003-06-03 2006-11-08 Cell Genesys Inc COMPOSITIONS AND METHODS FOR ENHANCED EXPRESSION OF RECOMBINANT POLYPEPTIDES FROM A SINGLE VECTOR USING A PEPTIDE CLEAVAGE SITE
US20090247475A1 (en) * 2004-03-05 2009-10-01 The Regents Of The University Of California Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies
CN106460009A (zh) * 2014-03-21 2017-02-22 小利兰·斯坦福大学托管委员会 无核酸酶的基因组编辑
US20220218843A1 (en) * 2018-08-10 2022-07-14 Logicbio Therapeutics, Inc. Non-disruptive gene therapy for the treatment of mma

Also Published As

Publication number Publication date
EP3955972A4 (en) 2023-01-11
EP3955972A1 (en) 2022-02-23
KR20220021906A (ko) 2022-02-22
MX2021012541A (es) 2021-11-12
WO2020214582A1 (en) 2020-10-22
IL287186A (en) 2021-12-01
MA55727A (fr) 2022-02-23
AU2020258371A1 (en) 2021-10-28
US20220308070A1 (en) 2022-09-29
JP2022529433A (ja) 2022-06-22
CN114072181A (zh) 2022-02-18
SG11202110584TA (en) 2021-10-28
CA3135666A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
GT201700246A (es) Métodos y kits para tratar la depresión
BR112019010342A2 (pt) composições do irna de serpina1 e métodos de uso destas
NI201700042A (es) Composiciones y métodos de uso para tratar trastornos metabólicos.
BR112021025676A2 (pt) Composições e métodos para tratar uma afecção mediada por th2 com o uso de prevotella
BR112016029041A2 (pt) terapia de combinação com inibidores de glutaminase
BR112018074979A2 (pt) composições de limpeza que compreendem enzimas
BR112018009954A2 (pt) materiais e métodos para o tratamento de miopatias baseadas em titinas e outras titinopatias
BR112018004620A2 (pt) moduladores da expressão de kras
BR112018011450A2 (pt) métodos e composições para o tratamento de um transtorno associado à serpinc1
BR112016019920A8 (pt) dispositivo médico implantável
BR112017010808A2 (pt) prevenção e tratamento de infecções microbianas
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
BR112015004465A2 (pt) sistemas, dispositivos e métodos para fornecer terapia com orientação de imagem
BR112016017509A2 (pt) composições e métodos compreendendo uma variante da enzima xilanase
CR20190387A (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
CO2019002909A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
BR112017021173A2 (pt) benefícios de produtividade de planta por compostos microbianos
BR112022005711A2 (pt) Métodos e composições para tratar uma doença ou transtorno
BR112018074283A2 (pt) composição e métodos para terapia com microbiota.
BR112017011425A2 (pt) aumento do crescimento de planta usando guars catiônico
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
CO2021007006A2 (es) Moduladores de la expresión de irf5
CO2020001801A2 (es) Tratamiento de afecciones óseas anormales en pacientes con deficiencia de esfingomielinasa ácida
BR112021020499A2 (pt) Monitoramento de terapia de gene
EA201592265A1 (ru) Маркер для ассоциированных с кислой сфингомиелиназой нарушений и его применения